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Metastasis is an intricate process by which a small number of cancer cells from the primary tumor site undergo numerous
alterations,whichenablesthemtoformsecondarytumorsatanotherandoftenmultiplesitesinthehost.Transitionofacancercell
from epithelial to mesenchymal phenotype is thought to be the ﬁrst step in the progression of metastasis. Recently, the recognition
ofcancerstemcellshasaddedtotheperplexityinunderstandingmetastasis,asstudiessuggestcancerstemcellstobetheoriginators
of metastasis. All current and investigative drugs have been unable to prevent or reverse metastasis, as a result of which most
metastatic cancers are incurable. A potential drug that can be considered is metformin, an oral hypoglycemic drug. In this review
we discuss the potential of metformin in targeting both epithelial to mesenchymal transition and cancer stem cells in combating
cancer metastases.
1.Introduction
Metastasis is the process by which cancer cells translocate
from their primary site to distant organs and establish sec-
ondary tumors. This simpliﬁed deﬁnition does not do justice
to the complex enigmatic phenomenon that still lacks clear
understanding. It is mainly because of metastasis that most
cancers become incurable and result in death. It is these
metastatic cells that escape the eﬀects of chemotherapy and
resultinpoorpatientoutcomes.Thus,adeeperknowledgeof
the process is crucial to devise therapeutic interventions that
will result in better outcomes and survival for patients with
metastatic disease.
Untilrecently,theinitiationofmetastasiswassolelyattri-
buted to the process of epithelial to mesenchymal (EMT)
transitionwhereadiﬀerentiated tumor cell transforms into a
more aggressive, motile, and resistant cell. A cell after under-
going EMT was thought to be able to break the conﬁnes of
its parent tumor and travel via lymphatic-blood system to a
new receptive environment, where it would establish a new
tumor. A full understanding of the EMT process is lacking.
Recently, research eﬀorts from a number of sources led to the
identiﬁcation of cancer stem cells (CSCs) [1, 2]. Some of the
data generated suggest that these CSC may be at the origin of
cancer metastasis [3–5].
All current and investigative drugs have been unable to
prevent or reverse metastasis. A better understanding of the
process is prerequisite to design successful drugs and stra-
tegies to manage the presently untreatable metastasis. One
potential drug that can be considered for this aspect is
metformin. Metformin is a well-established and widely pre-
scribed oral hypoglycemic drug. Recently, the drug has gain-
ed attention for its potential anticancer eﬀects [6–8]. In
addition to its antitumorigenic eﬀects, recent reports have
demonstrated inhibition of EMT genes and speciﬁc targeting
of stem cells by metformin, thus supporting its potential role
in ﬁghting cancer metastases.
In the present review, we brieﬂy discuss the basis of
metastasis with respect to EMT and CSC and summarize
some of the early studies on metformin showing its potential
to interfere both with the process of EMT and CSC.2 Journal of Oncology
2.EMTinMetastasis
Based on the canonical teaching, tumor metastasis is depen-
dent on a small number of cancer cells in the primary
tumor, which have the ability to undergo vast genetic
changes.Thesechangeswillultimatelyhelpthosecellsdetach
from the primary tumor location, implant at a separate
site, and generate secondary tumors [9]. In order for the
metastatic process to succeed, a cancer cell should be able
to survive under attachment-free conditions, migrate and
invade through the surrounding stroma, intravasate into the
vascular system, endure and extravasate into an advanta-
geous distant environment, adhere and proliferate [10]. Out
of this complex multistep process, the initial steps of a cell
gaining the ability of surviving adhesion-free, migrating, and
invading the extracellular matrix are the most crucial.
EMT was ﬁrst deﬁned as a developmental cell program
required in early embryogenesis [11]. In the carcinogenic
process, EMT pertains to an epithelial cancer cell losing its
epithelial makeup and acquiring mesenchymal character-
istics that confer on it survival and migratory advantages
[4, 11]. These include breakdown of the cell-cell junctions
and cytoskeleton alterations, providing the cell with motility
and invasiveness. This process works through a set of driving
transcription factors that include Snail, Slug, Twist, ZEB1/2,
and KLF-8 [3, 12–14]. The initial changes comprise the loss
of expression of the epithelial marker E-Cadherin [15, 16]
and gain in expression of Vimentin, N-Cadherin, and Fibro-
nectin [17, 18], all associated with the mesenchymal pheno-
type. The question of how these cells acquire these genes is
still at large. Investigators have shown that stimulation of
pathways like Wnt [19], Notch [20, 21], hypoxia [21, 22],
integrins [23], and PI3k-Akt [24] results in EMT-related
changes.
Identiﬁcation of the essential role of microenvironment
has also led to acknowledgement of its contribution in the
metastatic process [25, 26]. Various studies have shown that
tumor cells recruit and interact with the various components
of the stroma to create a microenvironment conducive to
pass and generate signals to initiate EMT [27]. Growth fac-
tors like TNF-α[28],TGF-β [29],FGF[30],EGF[31],PDGF
[32], and even IGF [33]h a v eb e e ns h o w nt oi n d u c eE M T
in myriad tumor cell lines. It has been suggested that the
surface tumor cells that are in direct contact with the stromal
components have the highest ability to proceed towards
EMT.
A clear pathway as to what initiates or drives EMT is still
unknown. Although EMT oﬀers a plausible explanation of
how cells become metastatic, a lot of questions still need to
be answered. What decides which cells will undergo EMT?
What is the ﬁrst cue required by a cell to initiate EMT? What
are the minimum alterations required to acquire metastatic
phenotype? What is the process involved in the tumors ori-
ginating from nonepithelial cells? Apart from the complexity
of going through EMT, the cell has to successfully navigate
through the blood vessels and reach a receptive seeding
ground where it needs to turn oﬀ the EMT, undergo reverse
mesenchymal to epithelial transition (MET) in order to
adhere and start proliferating [15, 17]. Does the process of
EMT also grant these additional characteristics? If not, how
do cells acquire these required traits to complete the journey
of metastasis?
Taking into account the intricate and enigmatic process
leading to metastasis, it is astonishing that it occurs frequen-
tly in the clinical setting.
3. Cancer Stem Cells in Metastasis
Recent understanding of the heterogeneous makeup of the
cancer cells in a tumor has revealed the presence of CSCs [1,
2].TheCSCsaredistinguishedbysomemajorpropertiesthat
include (i) self-renewing ability by asymmetric division (ii),
ability to diﬀerentiate into diverse phenotypes, (iii) ability to
initiate tumors from minute numbers, and (iv) high chemo-
resistance [1, 34–38]. The discovery of CSCs in cancer has
caused a major shift in the understanding of cancer biology
and is greatly aﬀecting the investigation of new therapeutics
aswell.Presently,thereisnoclearexplanationastotheorigin
of the CSCs. Many theories exist including that these cells
have changed (mutated) from the hematopoietic or tissue
speciﬁc or somatic stem cells, or that they have arisen due
to the regression of a diﬀerentiated tumor cell. The ﬁrst role
of CSC in cancer was described in hematologic malignan-
cies [39]. Lapidot et al. demonstrated that a small subset
of leukemic cells characterized by CD34+CD38− cell surface
markers were able to generate tumors in SCID mice, reﬂec-
ting disease similar to that seen in the original patient.
Recently, many studies have elegantly demonstrated the
self-renewal, resilient, and tumorigenic properties of CSCs
in tumors like breast [2], head and neck carcinoma [40],
brain tumor [41, 42], colon cancer [43, 44], melanoma
[45, 46], liver [47], prostate [48], and ovarian [49]. CSCs
isolated from diﬀerent tumors seem to display a variety cell
surface markers: colon and brain CSC have been isolated
using CD133+, prostate CSC with CD44+a2b1+ breast with
CD44+CD24−, ovarian with ALDH+, and so forth. In addi-
tion, these cells do coexpress pluripotent embryonic cell
markers like c-myc, Nanog, Sox2, Klf-4, Oct 4 and lin 28
[50–52]. The inherent capability to initiate a tumor from
a very small number of CSCs (counts of hundreds) in
immuno-compromised mice has been shown by various
researchers, a property not shared by the regular cancer cells.
Based on these ﬁndings, the aggressiveness and recurrence of
tumors are now being attributed to the minute population
of CSCs residing within the cancer cells. Although miniscule
in number, they have been anointed by many to be solely
responsible for driving and maintaining various tumors.
Thus, could it also be possible that it is these CSCs
that are also responsible for metastasis? If we observe the
aspects exhibited by a CSC, like initiating cancer from limit-
ed number of cells, longevity, enhanced resistance to the
apoptotic process, and remarkable motility, they appear to
be the ideal cells to cause metastasis. Supporting this is also
the increasing observations that cells that undergo EMT have
a CSC-like state [3–5, 53, 54], indicating that having pro-
perties germane to a stem cell are required for successful
metastasis. Experts in the ﬁeld have debated whether the
CSCs acquire/reexpress EMT traits when they are ready toJournal of Oncology 3
metastasize or the diﬀerentiated tumor cells revert back to a
more plastic stage based on their gain of EMT signature. Our
speculation is that both types of prospective-metastatic cells
exist within the tumor: the CSCs with inherent metastatic
potential and the acquired-EMT-turned-CSC tumor cells.
This knowledge gives arise to several other questions:
which cell actually initiates the process of metastasis? What
are the cues that would compel the cell (either CSC or EMT
tumor cell) to initiate metastasis? Is it the CSC/tumor cell
that ﬁrst initiates the cross-talk with the stromal microenvi-
ronment or is it the stroma that provides the initial signals
to the cell to change? These questions further confuse the
already clouded biology of metastasis. One hypothesis in
this regard suggests that the microenvironment around the
CSC speciﬁcally initiates the signals. The small population
of CSC seems to reside in a discrete milieu called the
“stem cell niche” [55], an ideal environment that maintains
self-renewing asymmetric dividing capability and provides
protection against stress and toxic insults [56]. Most CSC
niches are found adjoining blood vessels [46, 57], making
it more favorable for cells to intravasate and disseminate. It
has also been postulated that this type of microenvironment
induces the diﬀerentiated cancer cells to undergo EMT and
induce a CSC-like phenotype [58], which eventually results
in metastasizing of tumor cells.
This emerging concept of the CSCs being responsible for
metastasis along with their high resistance to conventional
chemotherapysuggeststhemtobetheultimatefoeincombat
against cancer. Thus, it is not surprising that therapies that
would speciﬁcally abolish these CSC are being actively inves-
tigated. In this regard, we discuss the potential role of met-
formin in targeting stem cells to control tumor progression
and more importantly limit metastasis.
4. Metformin in Cancer
Metformin belongs to a class of compounds called bigua-
nines that were ﬁrst isolated from the plant Galega oﬃcinalis
(French lilac or goat’s rue) known for its medicinal value
[59]. It was ﬁrst described in 1922 by Werner and Well, and
its glucose lowering action was ﬁrst documented in 1929
by Slotta and Tschesche. But it was only in the late 1950s
that metformin was established as a glucose-lowering drug
and became available for human consumption in UK. Slow-
ly, it gained worldwide interest and was approved by the
FDA in 1995 in the US [59, 60]. Today, it is the most wide-
ly prescribed antidiabetic drug for type 2 diabetes in the
world [60]. Metformin’s beneﬁcial eﬀects in diabetic patients
has been shown to be largely through repression of hepatic
gluconeogenesis, which reduces the glucose levels. In addi-
tion, it also increases insulin sensitivity and glucose uptake.
The mechanism behind these actions is largely believed to be
the inhibition of mitochondrial oxidative phosphorylation
leading to an ATP/AMP imbalance, which results in activa-
tion of the LKB1-AMPK pathway [61]. Activation of AMPK,
anenzymethatisthecentralregulatorofmetabolicpathways
[62], has been credited with the glucose lowering eﬀects seen
with metformin.
In the past decade, metformin has gained wide attention
for its anticancer properties. Numerous studies have shown
that in vitro treatment with metformin inhibited the growth
of myriad cancer cell lines including breast [6], glioma [7],
renal cell [63], pancreatic [64], colon [65], ovarian [8],
endometrial [8, 66], prostate [67], and lung [68]. Diverse
in vivo models have also been used to demonstrate the
antitumor abilities of metformin. One of the ﬁrst reports
was by Schneider et al. [69] where they showed metformin
to inhibit carcinogen induced pancreatic cancer in high-fat
diet fed hamsters. Another early study done in breast can-
cer mouse model showed that metformin treatment signif-
icantly decreased the tumor burden and accumulation of
mammary adenocarcinomas accompanied by increase in the
life span of HER-2/neu transgenic mice [70]. Lately, many
other xenograft and genetic in vivo models have been used
to describe the antigrowth eﬀect of metformin in various
tumor types [70–73]. Taking a step further, studies have also
shown the advantages of combining metformin with stand-
ard therapeutics like cisplatin [71], taxol [74], and doxoru-
bicin [75].
The main mechanism of tumor growth inhibition by
metformin has been attributed to activation of AMPK
leading to various downstream eﬀects that work together to
restrain tumor growth. Figure 1 brieﬂy enumerates the vari-
ous downstream eﬀects of metformin-mediated AMPK acti-
vation that have been inspected as being the mechanism(s)
by which tumor growth is inhibited. One of the established
and most investigated is the inhibition of the mTOR path-
way[76].Othermodulatorsofthecancerinhibitoryeﬀectsof
metformin via AMPK activation include cyclin D1, p21, p27,
Akt and p53 [8, 67]. AMPK has also been emerging as a chief
player in autophagy, a phenomenon shown to be involved in
tumorregulation[62,77–81].Inaddition,AMPKisrequired
in some tumors for the transcriptional activity of HIF-1, a
transcriptionfactorthatiscrucialforadaptationoftumorsto
hypoxic environment [82]. Metformin-mediated activation
of LKB1 could also result in the activation of other AMPK-
related kinases [83]. These AMPK-related kinases may be
performing functions similar to AMPK as shown by NUAK2
studies [84, 85].
Studies have also suggested that some of the eﬀects of
metformin are due to lowering of insulin levels [86], which
acts as a tumor-promoting factor. Metformin intake has also
been shown to create conditions of calorie restriction in the
host, an ameliorating factor for tumor growth [87]. Some
recently published data also shows metformin to be acting
through AMPK-independent mechanisms [8, 88, 89].
A strong body of epidemiologic evidence that supports
the anticancer beneﬁts of metformin comes from data col-
lected in diabetic patients. One of the ﬁrst studies published
by Evans et al. reported an association between metformin
intake and lower cancer incidence [90]. Another large 1000-
person retrospective study showed a signiﬁcant decrease in
cancer mortality for patients on metformin [91]. Recently,
this was supported by an analysis of the ZODIAC trial
data, where metformin takers were found to have a lower
cancer-related mortality [92]. In a single center retrospective
study, long-term intake of metformin (>36 months) was also4 Journal of Oncology
associated with signiﬁcant decrease in cancer risk [93]. Libby
et al. reported that metformin users had lower incidence
of cancer and delayed cancer occurrence time compared to
nonusers [94]. Many other studies have also shown similar
signiﬁcant correlations in pancreatic [95] and breast cancer
[96]. However, few other investigators failed to conﬁrm this
signiﬁcant trend of lower frequency of cancer in diabetic
patients [97–99].
A recent study of diabetic patients with colorectal cancer
showed decreased cancer-related mortality in patients on
metformin [100]. Studies have also inspected the association
betweenmetforminuseandoutcomesafterchemotherapyin
diﬀerent cancers types. Jiralerspong et al. found that diabetic
breastcancerpatientsreceivingmetforminalongwithtaxane
chemotherapy had a signiﬁcant improvement in pathologic
complete remission rate [101]. On the other hand, another
study showed no additional beneﬁt of metformin when
combined with neoadjuvant chemotherapy [102]. It is
important to realize that all of these reports present number
of limitations. Most of the patients included have type 2
diabetes mellitus but may also be taking other medication to
manage their diabetes or other illnesses. This confounds the
data as to the true eﬀects of metformin intake by itself.
The very interesting results of these retrospective studies
have prompted researchers to plan clinical trials that may
help further elucidate the antineoplastic eﬀect of metformin.
While many of them focus on breast cancer patients, few
includeothertumorslikeprostate,endometrial,kidney,pan-
creatic,andlung.AcompletelistasofOctober2011obtained
from http://www.clinicaltrials.gov/ is compiled in Table 1.A
couple of initial reports from these pilot studies show pro-
mising outcomes. In one study, nondiabetic breast cancer
patients were randomized to metformin or no treatment
for 2 weeks prior to undergoing breast surgery. Tumors of
patients on metformin showed a signiﬁcant reduction in the
proliferation marker, Ki-67, suggesting that metformin may
slow tumor cells proliferation. [103]. Another randomized
pilot study showed that the intake of metformin for one
month reduced the number of rectal aberrant crypt foci, an
endoscopic surrogate marker of colorectal cancer [104]. The
results of other clinical trials are eagerly awaited and would
hopefully provide further insights on the anticancer beneﬁts
of metformin.
5. Metformin againstMetastasis
Two theories have been proposed to explain metastasis: EMT
and CSC. Regardless which mechanism prevails, reports
showing metformin mitigating both EMT and CSC support
the potential use of metformin in preventing metastasis. Few
reportsinvestigatetheactionofmetforminagainstmetastasis
or stem cells.
5.1. Metformin Inhibits EMT. One of the ﬁrst studies on this
topic was by Beckner et al. where they reported metformin
to inhibit in vitro migration of glycolytic glioma cells [105].
Hwang et al. detailed the antimetastatic ability of metformin
in an in vitro s t u d yw i t hﬁ b r o s a r c o m ac e l l s[ 106]. They
demonstrated that metformin inhibited in vitro migration
and invasion of ﬁbrosarcoma cells by a CamK-dependent
pathway. Phoenix et al. studied the eﬀect of high calorie
diet on aggressiveness and metastasis of triple negative breast
cancer in a syngeneic in vivo model and its amelioration with
calorie restriction and metformin. In mice that were fed a
high-energy diet, metformin was able to limit the growth of
breast primary tumor but was unable to restrict metastatic
nodules in the lung [107]. On the other hand, a report from
Vazquez-Martin et al. [108]r e p o r t e dm e t f o r m i nt or e p r e s s
the metastasis-associated protein CD24, in a triple negative
breast cancer cell line. Another interesting study was done
in endometrial adenocarcinoma cells [109], using sera from
polycystic ovarian syndrome (PCOS) patients before and
after 6-month metformin therapy. PCOS is a major risk fac-
tor for endometrial cancer and is associated with metabolic
syndrome and inﬂammation [110]. The investigators report-
ed that sera from PCOS patients caused increased migration
in endometrial cancer cells, while sera from PCOS metform-
in-treatedpatientscausedsigniﬁcantinhibitionofmigration.
This was also associated with inhibition in NFκB, MMP-9,
and MMP-2 activities and decreased Akt and Erk1/2 phos-
phorylation. We have recently shown that metformin
reduced the number and size of metastatic lung nodules
in a xenograft model of ovarian cancer [71]. Activation
of the mTOR-S6K pathway has been associated with the
epithelial-mesenchymal transition phenotype. Overexpres-
sion of p70S6K has been correlated with underexpression of
E-cadherin and overexpression of N-cadherin and vimentin,
shown to be mediated by Snail [111]. Since treatment with
metformin has been shown to inhibit the mTOR-S6K path-
way, this could also be one possible mechanism by which
metformin inhibits EMT and metastasis. In a recent clinical
study,patientswithtriplenegativebreastcancerwhowereon
metforminhadalowerriskofdistantmetastasiscomparedto
women who were not on the drug [102].
5.2. Metformin Targets Stem Cells. The ﬁrst report deﬁning
metformin’s speciﬁc action against stem cells was published
by Hirsch et al. The authors demonstrated that breast cancer
stem cells, characterized by CD44high CD24low phenotype,
are susceptible to metformin at low doses that do not aﬀect
the tumor cells. They showed in vitro and in vivo that met-
formin can eliminate CSCs and virtually eradicates breast
tumors in mice when given along with doxorubicin [75].
Vaquez-Martin et al. presented evidence that CD44+CD24−
CSCsinHER2-positivebreastcancercellslines,thatareresis-
tant to trastuzumab, have selective sensitivity to low doses of
metformin. They further showed metformin to act synergis-
tically with trastuzumab to repress proliferation and survival
of CSC in HER2-positive breast cancer cell lines [112]. The
same group also demonstrated that metformin delays the
EMT-driven acquisition of stem cell phenotype and the
formation of self-renewing mammospheres that may repre-
sent “micro-tumors.” This occurred by inhibition of key
EMTtranscriptionfactorslikeZEB1,TWIST,Slug,andTGF-
β.T G F - β has been found to be involved in closely regulating
the process of EMT as well as appearance of CSC-like cells,
[3, 113, 114], particularly in breast cancer cells [115, 116].Journal of Oncology 5
Table 1
Identiﬁcation & Title Primary Goals Status
NCT01340300
Randomized Phase II study of exercise and metformin in
colorectal cancer survivors
Randomized study will compare interventions with
exercise and/or metformin, with a control arm. Insulin
levels and other blood markers will be estimated which
may indicate ecurrences
Not yet recruiting
NCT01266486
A Phase 2 single arm study to examine the eﬀects of
metformin on cancer metabolism in patients with early
stage breast cancer receiving neoadjuvant chemotherapy
Pre-surgery metformin will be given to patients for 3
weeks. Lipid metabolism of the tumor will be studied.
Patients will have option of taking metformin along with
neoadjuvant chemotherapy. Metformin induced eﬀects
in phosphorylation of S6K, 4E-BP-1 and AMPK will be
estimated by IHC
Recruiting
NCT01302002
A Phase 0 study regarding the biological eﬀects of use of
metformin in early breast cancer patients pre-surgery
After 3 weeks of metformin intake, in situ eﬀects of
metformin will be determined in women with operable
stage I or II breast cancer. Pre and post tissues will be
compared for proliferation (Ki67), apoptosis (TUNEL)
and fosforilate AKT
Recruiting
NCT00897884
Interventional study of clinical and biologic eﬀects of
metformin in early stage breast cancer
After 2-3 weeks of metformin intake, pre- and
post-operative biopsy samples will be compared for
proliferation
Recruiting
NCT01210911
A Phase II, randomized, placebo controlled study to
evaluate the eﬃcacy of the combination of gemcitabine,
erlotinib and metformin in patients with locally
advanced and metastatic pancreatic cancer
Survival after 6 months of combinational therapy will be
determined Recruiting
NCT01440127
Phase I randomized clinical trial evaluating the impact of
pretreatment with metformin on colorectal cancer stem
cells and related pharmacodynamic markers
Pateints will randomly receive metformin pre-procedure
for approximately 1 week. Cancer stem cells will be
isolated from blood. Glucose will be measured
Recruiting
NCT01205672
Interventional non-randomized evaluation of the
molecular eﬀects of metformin on the endometrium in
patients with endometrial cancer
30 days before surgery patients will be given metformin.
Molecular eﬀects of metformin will be measured by
changes in insulin/glucose metabolism on the mTOR
signaling in endometrium of women with endometrial
cancer and high body mass index
Recruiting
NCT00984490
Interventional pre-surgical trial of metformin in patients
with operable breast cancer
After 1–3 weeks of metformin intake, pre- and
post-operative biopsy samples will be compared for
proliferation ( Ki67) in women with stage I or stage II
breast cancer that can be removed by surgery
Recruiting
NCT01310231
A randomized Phase II, double blind, trial of standard
chemotherapy with metformin (vs. placebo) in women
with metastatic breast cancer receiving ﬁrst or second
line chemotherapy with anthracycline, taxane, platinum
or capecitabine based regimens
Metformin will be given along with standard
chemotherapy. Progression free survival will be assessed
up to 3 years
Recruiting6 Journal of Oncology
Table 1: Continued.
Identiﬁcation & Title Primary Goals Status
NCT01433913
Phase II study of metformin in a pre-prostatectomy
prostate cancer cohort
Metformin will be given for 4 to 12 weeks before surgical
removal of the prostate gland. Levels of metformin will
be detected in prostate tissue. Physiological and cellular
abnormalities in prostate tissue removed at surgery will
be measured
Not yet recruiting
NCT01333852
Randomized Phase II study of paclitaxel plus metformin
or placebo for the treatment of platinum-refractory,
recurrent or metastatic head and neck neoplasms
Various combinations will be given to patients and
Disease Progression-free survival at 12 weeks and 6
months will be recorded
Recruiting
NCT00659568
A Phase I study of temsirolimus in combination with
metformin in advanced solid tumours
Maximum tolerated dose and recommended phase II
dose of metformin along with temsirolimus will be
estimated. Antitumor activity, including tumor response
rate and time to progression will be recorded
Completed
NCT01215032
Prospective study of metformin in castration-resistant
prostate cancer
Metformin will be given along with androgen
deprivation therapy in a 2-year study. PSA (prostate
speciﬁc antigen) response will be monitored
Recruiting
NCT01101438
A Phase III randomized trial of metformin versus
placebo on recurrence and survival in early stage breast
cancer
Patients will intake metformin for 5 years. Invasive
disease-free survival and Overall survival will be
recorded
Recruiting
NCT00881725
A Phase II, open label assessment of neoadjuvant
intervention with metformin against tumour expression
of signaling prostate cancer
Patients will take metformin for 4–12 weeks prior to
Radical Prostatectomy. Diﬀerence in P-AKT staining and
other parameters will be measured under pre- and
post-surgery conditions
Active, not
recruiting
NCT01087983
Phase 1 trial of lapatinib in combination with (1)
sirolimus or (2) metformin in advanced cancer
Maximum Tolerated Dose (MTD) of Lapatinib with the
combinations will be calculated Recruiting
NCT01243385
Metformin in castration resistant prostate cancer. A
multicenter Phase II trial
Safety of giving metformin as ﬁrst-line therapy in
treating patients with locally advanced or metastatic
prostate cancer will be assesed. Progression-free survival
(PFS) at 12 weeks and at later time points with
continuation of therapy will be recorded
Recruiting
NCT01341886
Eﬀect of metformin on decrement in levothyroxin dose
required for thyroid stimulating hormone (TSH)
suppression in patients with diﬀerentiated thyroid cancer
Metformin will be given as an additional drug to
levothyroxin in order to decrease levothyroxine dosage
by 30%. Metformin’s eﬀect in inducing TSH suppression
without change in T3 and T4 concentration will be
estimated
Completed
NCT01430351
A Phase I lead-in to a 2 ×2 × 2 factorial rrial of dose
dense temozolomide (TMZ), memantine (MEMTN),
meﬂoquine (MFLOQ), and metformin as post-radiation
adjuvant therapy of glioblastoma multiforme
The study will determine the safety and tolerability of
TMZ in combination with Metformin and/or (MFLOQ)
and/or MEMTN in patients receiving adjuvant therapy
after completing external beam radiotherapy for newly
diagnosed glioblastoma multiforme. Median progression
free survival at 6, 12, and 18 months will be measured
RecruitingJournal of Oncology 7
Table 1: Continued.
Identiﬁcation & Title Primary Goals Status
NCT01167738
A randomized Phase II study of chemotherapy and/or
not metformin in metastatic pancreatic cancer
Studying giving cisplatin, epirubicin, capecitabine, and
gemcitabine together with metformin to see how well it
works compared to chemotherapy alone in treating
patients with metastatic pancreatic cancer.
Progression-free survival at 6 months and overall
survival will be estimated
Recruiting
NCT01447927
A Phase II trial of metformin in preventing esophageal
cancer in patients with barrett esophagus
Eﬀect of metformin intake for 2–12 weeks in preventing
esophageal cancer in patients with Barrett esophagus will
be observed. Percent change in the mean pS6K1
immunostaining will be taken as marker
Not yet recruiting
NCT01312467
A Phase IIA trial of metformin for colorectal cancer risk
reduction among patients with a history of colorectal
adenomas and elevated body mass index
To determine if a 12-week intervention of oral
metformin treatment among obese patients with a
history of colorectal adenomas results in at least a 35%
decrease in colorectal mucosa. Activated pS6serine235
from baseline as assessed via immunostaining in pre and
post biopsies
Recruiting
NCT00909506
A Phase II trial of eﬃcacy and safety of adjuvant
metformin for operable breast cancer patients
Metformin will be given to patients of operable breast
cancer patients with overweight or pre-DM for 24 weeks,
to test the eﬃcacy and safety of adjuvant metformin and
weight loss
Recruiting
NCT00930579
A Phase II pre-surgical intervention study for evaluating
the eﬀect of metformin on breast cancer proliferation
Eﬀects of metformin on AMPK/mTOR signaling
pathway and insulin levels will be measured after 2 weeks
on metformin
Recruiting
NCT01442870
A Phase I prospective evaluation of clinical safety of
combining metformin with anticancer chemotherapy
Cytologically documented cancer patients will be given
metformin for 3 weeks to determine whether metformin
can be safely added to a chemotherapy regimen that is
previously well tolerated. The rate of dose limiting
toxicities will be compared
Recruiting
NCT01324180
A Phase I window, dose escalating and safety trial of
metformin in combination with induction
chemotherapy in relapsed refractory acute lymphoblastic
leukemia: metformin with induction chemotherapy of
vincristine, dexamethasone, doxorubicin, and
PEG-asparaginase (VPLD)
Clinical and biological eﬀects of metformin in
combination with standard systemic chemotherapy in
relapsed ALL patients that have a dismal outcome will be
estimated. A dose escalation study to ﬁnd the Maximum
Tolerated Dose (MTD) of metformin in conjunction
with ALL therapy. Complete Remission will be taken as
end point
Recruiting
Metformin was also able to inhibit the progression of TGF-
β-induced EMT changes by retaining the expression of E-
cadherin and preventing concurrent appearance of vimentin
expression, two events that occur when an epithelial cancer
cell converts into a mesenchymal cell [116].
There has been some suggestions that cancer stem cells
may be regulated by the mitochondria and metabolic repro-
gramming [117, 118]. Certain metabolites like high-energy
lactanes and ketones promote the “stemness” of cancer
cells by upregulating stemness-associated genes as well as
genes found in embryonic stem cells. These gene signatures,
inducedketoneandlactate,werecorrelatedwithpoorpatient
survival. It was speculated that this was due to fueling of the
tumors by pushing them towards oxidative phosphorylation
[119]. With this respect, metformin is known to interfere
with the mitochondrial process and can attenuate the meta-
bolicchangesenabledbyketone/lactatemetabolites(orother
metabolites).
These initial studies demonstrating the eﬀects of met-
formin against CSCs look promising and need to be8 Journal of Oncology
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results in myriad eﬀects that include (i) inhibition of mTOR, resulting in inhibition of protein synthesis and cell growth; (ii) activation of
p53andp21alongwithinhibitionofcyclins,resultingincellcyclearrest;(iii)inhibitionoflipidandsterolbiosyntheticpathways;(iv)having
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Figure 2: Metformin can inhibit appearance of metastasis by (1) limiting growth of the primary tumor; (2) inhibiting EMT; (3) eradicating
cancer stem cells.
expanded to gain further insight into the speciﬁc action and
the mechanism involved. Overall, metformin seems to be a
viable therapeutic choice to target metastasis as it seems to
aﬀect both the EMT and cancer stem cells (Figure 2), both
believed to be focal points for metastasis.
6. Concluding Remarks
Ourpresentknowledge is farfromacompleteunderstanding
of the complex and multifaceted process of metastasis. The
discovery of CSC population oﬀers an explanation for some
of the unique behaviors seen in cancer. The emerging studies
showing eradication of animal tumors by double targeting of
cancer cells and CSCs provide signiﬁcant hope for the future.
The emergence of metformin as a potential anticancer
and cancer-preventive therapeutic tool is exciting. With the
added beneﬁts of being readily available, economical, and
easily tolerated with good safety proﬁle, it can be eﬀortlessly
transitioned from bench to bedside for cancer therapy.
Acknowledgment
R. Rattan is supported by DOD-OCRMP no. OC100333 and
OC100335 Grants.Journal of Oncology 9
References
[1] D. Bonnet and J. E. Dick, “Human acute myeloid leukemia
is organized as a hierarchy that originates from a primitive
hematopoietic cell,” Nature Medicine, vol. 3, no. 7, pp. 730–
737, 1997.
[ 2 ] M .A l - H a j j ,M .S .W i c h a ,A .B e n i t o - H e r n a n d e z ,S .J .
Morrison, and M. F. Clarke, “Prospective identiﬁcation of
tumorigenic breast cancer cells,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 100,
no. 7, pp. 3983–3988, 2003.
[3] S. A. Mani, W. Guo, M. J. Liao et al., “The epithelial-mesen-
chymal transition generates cells with properties of stem
cells,” Cell, vol. 133, no. 4, pp. 704–715, 2008.
[4] B. G. Hollier, K. Evans, and S. A. Mani, “The epithelial-to-
mesenchymal transition and cancer stem cells: a coalition
against cancer therapies,” Journal of Mammary Gland Biology
and Neoplasia, vol. 14, no. 1, pp. 29–43, 2009.
[ 5 ]G .J .K l a r m a n n ,E .M .H u r t ,L .A .M a t h e w se ta l . ,“ I n v a s i v e
prostate cancer cells are tumor initiating cells that have a
stem cell-like genomic signature,” Clinical and Experimental
Metastasis, vol. 26, no. 5, pp. 433–446, 2009.
[6] M. Zakikhani, R. Dowling, I. G. Fantus, N. Sonenberg, and
M. Pollak, “Metformin is an AMP kinase-dependent growth
inhibitor for breast cancer cells,” Cancer Research, vol. 66, no.
21, pp. 10269–10273, 2006.
[7] A. Isakovic, L. Harhaji, D. Stevanovic et al., “Dual antiglioma
action of metformin: cell cycle arrest and mitochondria-
dependent apoptosis,” Cellular and Molecular Life Sciences,
vol. 64, no. 10, pp. 1290–1302, 2007.
[8] R. Rattan, S. Giri, L. C. Hartmann, and V. Shridhar, “Met-
formin attenuates ovarian cancer cell growth in an AMP-
kinasedispensablemanner,”JournalofCellularandMolecular
Medicine, vol. 15, no. 1, pp. 166–178, 2011.
[9] C. Coghlin and G. I. Murray, “Current and emerging
concepts in tumour metastasis,” Journal of Pathology, vol.
222, no. 1, pp. 1–15, 2010.
[10] C. L. Chaﬀe ra n dR .A .W e i n b e r g ,“ Ap e r s p e c t i v eo nc a n c e r
cell metastasis,” Science, vol. 331, no. 6024, pp. 1559–1564,
2011.
[11] J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto,
“Epithelial-mesenchymal transitions in development and
disease,” Cell, vol. 139, no. 5, pp. 871–890, 2009.
[12] N. K. Kurrey, S. P. Jalgaonkar, A. V. Joglekar et al., “Snail and
slug mediate radioresistance and chemoresistance by anta-
gonizing p53-mediated apoptosis and acquiring a stem-like
phenotype in ovarian cancer cells,” Stem Cells, vol. 27, no. 9,
pp. 2059–2068, 2009.
[13] X. Wang, M. Zheng, G. Liu et al., “Kr¨ uppel-like factor 8
induces epithelial to mesenchymal transition and epithelial
cell invasion,” Cancer Research, vol. 67, no. 15, pp. 7184–
7193, 2007.
[14] H. Wallerand, G. Robert, G. Pasticier et al., “The epithelial-
mesenchymal transition-inducing factor TWIST is an attrac-
tive target in advanced and/or metastatic bladder and pro-
state cancers,” Urologic Oncology, vol. 28, no. 5, pp. 473–479,
2010.
[15] J. J. Christiansen and A. K. Rajasekaran, “Reassessing epithe-
lialtomesenchymaltransitionasaprerequisiteforcarcinoma
invasion and metastasis,” Cancer Research, vol. 66, no. 17, pp.
8319–8326, 2006.
[16] V. Bol´ o s ,H .P e i n a d o ,M .A .P ´ erez-Moreno, M. F. Fraga,
M. Esteller, and A. Cano, “The transcription factor Slug
represses E-cadherin expression and induces epithelial to
mesenchymal transitions: a comparison with Snail and E47
repressors,” Journal of Cell Science, vol. 116, no. 3, pp. 499–
511, 2003.
[17] H. Hugo, M. L. Ackland, T. Blick et al., “Epithelial—Mesen-
chymal and mesenchymal—Epithelial transitions in carci-
noma progression,” Journal of Cellular Physiology, vol. 213,
no. 2, pp. 374–383, 2007.
[18] J.P.ThieryandJ.P.Sleeman,“Complexnetworksorchestrate
epithelial-mesenchymal transitions,”Nature Reviews Molecu-
lar Cell Biology, vol. 7, no. 2, pp. 131–142, 2006.
[19] E. Vincan and N. Barker, “The upstream components of
the Wnt signalling pathway in the dynamic EMT and MET
associated with colorectal cancer progression,” Clinical and
Experimental Metastasis, vol. 25, no. 6, pp. 657–663, 2008.
[20] C. G¨ ung¨ or, H. Zander, K. E. Eﬀenberger et al., “Notch signal-
ing activated by replication stress-induced expression of
Midkine drives epithelial-mesenchymal transition and
chemoresistance in pancreatic cancer,” Cancer Research, vol.
71, no. 14, pp. 5009–5019, 2011.
[21] D. F. Higgins, K. Kimura, W. M. Bernhardt et al., “Hypoxia
promotes ﬁbrogenesis in vivo via HIF-1 stimulation of epi-
thelial-to-mesenchymal transition,” Journal of Clinical Inves-
tigation, vol. 117, no. 12, pp. 3810–3820, 2007.
[22] D. Luo, J. Wang, J. Li, and M. Post, “Mouse snail is a target
gene for HIF,” Molecular Cancer Research, vol. 9, no. 2, pp.
234–245, 2011.
[23] F. A. Mamuya and M. K. Duncan, “alphaV integrins and
TGF-beta induced EMT; a circle of regulation,” Journal of
Cellular and Molecular Medicine, vol. 16, no. 3, pp. 445–455,
2012.
[24] H. Y. Irie, R. V. Pearline, D. Grueneberg et al., “Distinct roles
of Akt1 and Akt2 in regulating cell migration and epithelial-
mesenchymal transition,”J o urnalo fC ellBio logy, vol.171,no.
6, pp. 1023–1034, 2005.
[25] J. Yang and R. A. Weinberg, “Epithelial-mesenchymal transi-
tion: at the crossroads of development and tumor metasta-
sis,” Developmental Cell, vol. 14, no. 6, pp. 818–829, 2008.
[26] Y. Jing, Z. Han, S. Zhang, Y. Liu, and L. Wei, “Epithelial-
Mesenchymal Transition in tumor microenvironment,” Cell
and Bioscience, vol. 1, p. 29, 2011.
[27] R. N. Kaplan, S. Raﬁi, and D. Lyden, “Preparing the ”soil”:
the premetastatic niche,” Cancer Research, vol. 66, no. 23, pp.
11089–11093, 2006.
[ 2 8 ] R .D o n g,Q .W a n g,X .L .H e ,Y .K .C h u ,J .G .L u ,a n dQ .J .M a ,
“RoleofnuclearfactorkappaBandreactiveoxygenspeciesin
the tumor necrosis factor-α-induced epithelial-mesenchymal
transition of MCF-7 cells,” Brazilian Journal of Medical and
Biological Research, vol. 40, no. 8, pp. 1071–1078, 2007.
[29] P. J. Miettinen, R. Ebner, A. R. Lopez, and R. Derynck, “TGF-
β induced transdiﬀerentiation of mammary epithelial cells to
mesenchymal cells: involvement of type I receptors,” Journal
of Cell Biology, vol. 127, no. 6, pp. 2021–2036, 1994.
[30] C. Billottet, M. Tueﬀerd, D. Gentien et al., “Modulation of
several waves of gene expression during FGF-1 induced epi-
thelial-mesenchymal transition of carcinoma cells,” Journal
of Cellular Biochemistry, vol. 104, no. 3, pp. 826–839, 2008.
[31] Z. Cai, Q. Wang, Y. Zhou, L. Zheng, J. F. Chiu, and Q. Y. He,
“Epidermal growth factor-induced epithelial-mesenchymal
transition in human esophageal carcinoma cells—a model
for the study of metastasis,” Cancer Letters, vol. 296, no. 1,
pp. 88–95, 2010.
[32] D. Kong, Z. Wang, S. H. Sarkar et al., “Platelet-derived
growth factor-D overexpression contributes to epithelial-
mesenchymal transition of PC3 prostate cancer cells,” Stem
Cells, vol. 26, no. 6, pp. 1425–1435, 2008.10 Journal of Oncology
[33] L. A. Walsh and S. Damjanovski, “IGF-1 increases invasive
potential of MCF 7 breast cancer cells and induces activation
of latent TGF-beta1 resulting in epithelial to mesenchymal
transition,” Cell Communication and Signaling, vol. 9, no. 1,
p. 10, 2011.
[34] E. Charafe-Jauﬀret, C. Ginestier, F. Iovino et al., “Breast
cancer cell lines contain functional cancer stem sells with
metastatic capacity and a distinct molecular signature,”
Cancer Research, vol. 69, no. 4, pp. 1302–1313, 2009.
[ 3 5 ]R .P a n g ,W .L .L a w ,A .C .Y .C h ue ta l . ,“ As u b p o p u l a t i o no f
CD26+ cancer stem cells with metastatic capacity in human
colorectal cancer,” Cell Stem Cell, vol. 6, no. 6, pp. 603–615,
2010.
[36] P. Marcato, C. A. Dean, P. Da et al., “Aldehyde dehydrogenase
activity of breast cancer stem cells is primarily due to isoform
ALDH1A3 and its expression is predictive of metastasis,”
Stem Cells, vol. 29, no. 1, pp. 32–45, 2011.
[37] A. Schulenburg, K. Br¨ amswig, H. Herrmann et al., “Neo-
plastic stem cells: current concepts and clinical perspectives,”
Critical Reviews in Oncology/Hematology,v o l .7 6 ,n o .2 ,p p .
79–98, 2010.
[38] T. Tanei, K. Morimoto, K. Shimazu et al., “Association of
breastcancerstemcellsidentiﬁedbyaldehydedehydrogenase
1 expression with resistance to sequential paclitaxel and
epirubicin-based chemotherapy for breast cancers,” Clinical
Cancer Research, vol. 15, no. 12, pp. 4234–4241, 2009.
[39] T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating
human acute myeloid leukaemia after transplantation into
SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994.
[40] M. E. Prince, R. Sivanandan, A. Kaczorowski et al., “Identiﬁ-
cation of a subpopulation of cells with cancer stem cell pro-
perties in head and neck squamous cell carcinoma,” Proceed-
ings of the National Academy of Sciences of the United States of
America, vol. 104, no. 3, pp. 973–978, 2007.
[41] S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identiﬁcation of
human brain tumour initiating cells,” Nature, vol. 432, no.
7015, pp. 396–401, 2004.
[42] D. Beier, P. Hau, M. Proescholdt et al., “CD133+ and
CD133− glioblastoma-derived cancer stem cells show diﬀer-
ential growth characteristics and molecular proﬁles,” Cancer
Research, vol. 67, no. 9, pp. 4010–4015, 2007.
[43] C. A. O’Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A
human colon cancer cell capable of initiating tumour growth
in immunodeﬁcient mice,” Nature, vol. 445, no. 7123, pp.
106–110, 2007.
[44] L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi et al., “Identiﬁca-
tion and expansion of human colon-cancer-initiating cells,”
Nature, vol. 445, no. 7123, pp. 111–115, 2007.
[45] T. Schatton, G. F. Murphy, N. Y. Frank et al., “Identiﬁcation
of cells initiating human melanomas,” Nature, vol. 451, no.
7176, pp. 345–349, 2008.
[46] E. Quintana, M. Shackleton, M. S. Sabel, D. R. Fullen, T. M.
Johnson, and S. J. Morrison, “Eﬃcient tumour formation by
singlehumanmelanomacells,”Nature,vol.456,no.7222,pp.
593–598, 2008.
[47] S. Ma, W. C. Kwok, T. K. W. Lee et al., “Aldehyde dehydrog-
enase discriminates the CD133 liver cancer stem cell popu-
lations,” Molecular Cancer Research, vol. 6, no. 7, pp. 1146–
1153, 2008.
[48] L. Patrawala, T. Calhoun, R. Schneider-Broussard et al.,
“Highly puriﬁed CD44+ prostate cancer cells from xenograft
human tumors are enriched in tumorigenic and metastatic
progenitor cells,” Oncogene, vol. 25, no. 12, pp. 1696–1708,
2006.
[49] C. N. Landen, B. Goodman, A. A. Katre et al., “Targeting
aldehyde dehydrogenase cancer stem cells in ovarian cancer,”
Molecular Cancer Therapeutics, vol. 9, no. 12, pp. 3186–3199,
2010.
[50] T.Aoi,K.Yae,M.Nakagawaetal.,“Generationofpluripotent
stem cells from adult mouse liver and stomach cells,” Science,
vol. 321, no. 5889, pp. 699–702, 2008.
[51] J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., “Induced
pluripotent stem cell lines derived from human somatic
cells,” Science, vol. 318, no. 5858, pp. 1917–1920, 2007.
[52] Y. Junying, H. Kejin, S. O. Kim et al., “Human induced pluri-
potent stem cells free of vector and transgene sequences,”
Science, vol. 324, no. 5928, pp. 797–801, 2009.
[53] A.P.Morel,M.Li` evre,C.Thomas,G.Hinkal,S.Ansieau,and
A. Puisieux, “Generation of breast cancer stem cells through
epithelial-mesenchymal transition,” PLoS ONE,v o l .3 ,n o .8 ,
Article ID e2888, 2008.
[54] M. Santisteban, J. M. Reiman, M. K. Asiedu et al., “Immune-
induced epithelial to mesenchymal transition in vivo gener-
ates breast cancer stem cells,” Cancer Research, vol. 69, no. 7,
pp. 2887–2895, 2009.
[55] N. Y. Frank, T. Schatton, and M. H. Frank, “The therapeutic
promise of the cancer stem cell concept,” Journal of Clinical
Investigation, vol. 120, no. 1, pp. 41–50, 2010.
[56] M. McGovern, R. Voutev, J. Maciejowski, A. K. Corsi, and
E. J. A. Hubbard, “A ”latent niche” mechanism for tumor
initiation,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 106, no. 28, pp. 11617–
11622, 2009.
[57] T. Brabletz, A. Jung, S. Spaderna, F. Hlubek, and T. Kirchner,
“Migrating cancer stem cells—an integrated concept of
malignant tumour progression,” Nature Reviews Cancer, vol.
5, no. 9, pp. 744–749, 2005.
[58] C.H.M.Jamieson,L.E.Ailles,S.J.Dyllaetal.,“Granulocyte-
macrophage progenitors as candidate leukemic stem cells in
blast-crisis CML,” New England Journal of Medicine, vol. 351,
no. 7, pp. 657–667, 2004.
[59] L. A. Witters, “The blooming of the French lilac,” Journal of
Clinical Investigation, vol. 108, no. 8, pp. 1105–1107, 2001.
[60] T. V. Kourelis and R. D. Siegel, “Metformin and cancer: new
applications for an old drug,” Medical Oncology, pp. 1–14,
2011.
[61] R. J. Shaw, K. A. Lamia, D. Vasquez et al., “Medicine: the
kinase LKB1 mediates glucose homeostasis in liver and ther-
apeutic eﬀects of metformin,” Science, vol. 310, no. 5754, pp.
1642–1646, 2005.
[62] D. G. Hardie, “AMP-activated protein kinase—an energy
sensor that regulates all aspects of cell function,” Genes &
Development, vol. 25, no. 18, pp. 1895–1908, 2011.
[63] J. Liu, M. Li, B. Song et al., “Metformin inhibits renal cell
carcinoma in vitro and in vivo xenograft,” Urologic Oncology.
In press.
[64] L. W. Wang, Z. S. Li, D. W. Zou, Z. D. Jin, J. Gao, and G.
M. Xu, “Metformin induces apoptosis of pancreatic cancer
cells,” World Journal of Gastroenterology, vol. 14, no. 47, pp.
7192–7198, 2008.
[65] M.Zakikhani,R.J.Dowling,N.Sonenberg,andM.N.Pollak,
“The eﬀects of adiponectin and metformin on prostate and
colon neoplasia involve activation of AMP-activated protein
kinase,” Cancer Prevention Research, vol. 1, no. 5, pp. 369–
375, 2008.
[66] L. A. Cantrell, C. Zhou, A. Mendivil, K. M. Malloy, P. A.
Gehrig,andV.L.Bae-Jump,“Metforminisapotentinhibitor
of endometrial cancer cell proliferation-implications for aJournal of Oncology 11
novel treatment strategy,” Gynecologic Oncology, vol. 116, no.
1, pp. 92–98, 2010.
[67] I. B. Sahra, K. Laurent, A. Loubat et al., “The antidiabetic
drug metformin exerts an antitumoral eﬀect in vitro and in
vivo through a decrease of cyclin D1 level,” Oncogene, vol. 27,
no. 25, pp. 3576–3586, 2008.
[68] C. Algire, M. Zakikhani, M. J. Blouin, J. H. Shuai, and
M. Pollak, “Metformin attenuates the stimulatory eﬀect of
a high-energy diet on in vivo LLC1 carcinoma growth,”
Endocrine-Related Cancer, vol. 15, no. 3, pp. 833–839, 2008.
[69] M. B. Schneider, H. Matsuzaki, J. Haorah et al., “Prevention
of pancreatic cancer induction in hamsters by metformin,”
Gastroenterology, vol. 120, no. 5, pp. 1263–1270, 2001.
[70] V. N. Anisimov, L. M. Berstein, P. A. Egormin et al., “Eﬀect
of metformin on life span and on the development of
spontaneous mammary tumors in HER-2/neu transgenic
mice,” Experimental Gerontology, vol. 40, no. 8-9, pp. 685–
693, 2005.
[71] S. A. Mullany, M. Moslemi-Kebria, R. Rattan et al., “Expres-
sion and functional signiﬁcance of HtrA1 loss in endometrial
cancer,” Clinical Cancer Research, vol. 17, no. 3, pp. 427–436,
2011.
[ 7 2 ]R .M .M e m m o t t ,J .R .M e r c a d o ,C .R .M a i e r ,S .K a w a b a t a ,
S. D. Fox, and P. A. Dennis, “Metformin prevents tobacco
carcinogen-induced lung tumorigenesis,” Cancer Prevention
Research, vol. 3, no. 9, pp. 1066–1076, 2010.
[73] B. X. Tan, W. X. Yao, J. Ge et al., “Prognostic inﬂuence of
metforminasﬁrst-linechemotherapyforadvancednonsmall
cell lung cancer in patients with type 2 diabetes,” Cancer, vol.
117, no. 22, pp. 5103–5111, 2011.
[74] G. Z. Rocha, M. M. Dias, E. R. Ropelle et al., “Metformin
ampliﬁes chemotherapy-induced AMPK activation and anti-
tumoralgrowth,”ClinicalCancerResearch,vol.17,no.12,pp.
3993–4005, 2011.
[75] H. A. Hirsch, D. Iliopoulos, P. N. Tsichlis, and K. Struhl,
“Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and
prolong remission,” Cancer Research, vol. 69, no. 19, pp.
7507–7511, 2009.
[76] A. Tomimoto, H. Endo, M. Sugiyama et al., “Metformin
suppresses intestinal polyp growth in ApcMin/+ mice,”
Cancer Science, vol. 99, no. 11, pp. 2136–2141, 2008.
[77] R.Viana,C.Aguado,I.Estebanetal.,“RoleofAMP-activated
protein kinase in autophagy and proteasome function,”
Biochemical and Biophysical Research Communications, vol.
369, no. 3, pp. 964–968, 2008.
[78] K. Janjetovic, L. Vucicevic, M. Misirkic et al., “Metformin
reduces cisplatin-mediated apoptotic death of cancer cells
through AMPK-independent activation of Akt,” European
Journal of Pharmacology, vol. 651, no. 1-3, pp. 41–50, 2011.
[79] Z. Xie, K. Lau, B. Eby et al., “Improvement of cardiac func-
tions by chronic metformin treatment is associated with
enhanced cardiac autophagy in diabetic OVE26 mice,”
Diabetes, vol. 60, no. 6, pp. 1770–1778, 2011.
[80] J. H. Park, M. Y. Ahn, T. H. Kim et al., “A new synthetic
HDAC inhibitor, MHY218, induces apoptosis or autophagy-
related cell death in tamoxifen-resistant MCF-7 breast cancer
cells,” Investigational New Drugs. In press.
[81] A. Notte, L. Leclere, and C. Michiels, “Autophagy as a medi-
atorofchemotherapy-inducedcelldeathincancer,”Biochem-
ical Pharmacology, vol. 82, no. 5, pp. 427–434, 2011.
[82] S. N. Jung, W. K. Yang, J. Kim et al., “Reactive oxygen species
stabilize hypoxia-inducible factor-1 alpha protein and stimu-
late transcriptional activity via AMP-activated protein kinase
in DU145 human prostate cancer cells,” Carcinogenesis, vol.
29, no. 4, pp. 713–721, 2008.
[83] N. J. Bright, C. Thornton, and D. Carling, “The regulation
and function of mammalian AMPK-related kinases,” Acta
Physiologica, vol. 196, no. 1, pp. 15–26, 2009.
[84] T. Namiki, A. Tanemura, J. C. Valencia et al., “AMP kinase-
related kinase NUAK2 aﬀects tumor growth, migration, and
clinical outcome of human melanoma,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 108, no. 16, pp. 6597–6602, 2011.
[85] G. B. W. Wertheim, T. W. Yang, T. C. Pan et al., “The Snf1-
related kinase, Hunk, is essential for mammary tumor meta-
stasis,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 106, no. 37, pp. 15855–15860,
2009.
[86] L.M.Berstein,“Metformin,insulin,breastcancerandmore,”
Future Oncology, vol. 5, no. 3, pp. 309–312, 2009.
[87] Z. Zhu et al., “Metformin as an energy restriction mimetic
agent for breast cancer prevention,” Journal of Carcinogenesis,
vol. 10, p. 17, 2011.
[88] I. B. Sahra, C. Regazzetti, G. Robert et al., “Metformin,
independent of AMPK, induces mTOR inhibition and cell-
cycle arrest through REDD1,” Cancer Research, vol. 71, no.
13, pp. 4366–4372, 2011.
[89] A. Yasmeen, M. C. Beauchamp, E. Piura, E. Segal, M. Pollak,
and W. H. Gotlieb, “Induction of apoptosis by metformin
in epithelial ovarian cancer: involvement of the Bcl-2 family
proteins,” Gynecologic Oncology, vol. 121, no. 3, pp. 492–498,
2011.
[90] J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R.
Alessi, and A. D. Morris, “Metformin and reduced risk of
cancer in diabetic patients,” British Medical Journal, vol. 330,
no. 7503, pp. 1304–1305, 2005.
[91] S. L. Bowker, S. R. Majumdar, P. Veugelers, and J. A. Johnson,
“Increased cancer-related mortality for patients with type 2
diabeteswhousesulfonylureasorinsulin,”DiabetesCare,vol.
29, no. 2, pp. 254–258, 2006.
[ 9 2 ]G .W .D .L a n d m a n ,N .K l e e f s t r a ,K .J .J .V a nH a t e r e n ,K .
H. Groenier, R. O. B. Gans, and H. J. G. Bilo, “Metformin
associated with lower cancer mortality in type 2 diabetes:
zodiac-16,” Diabetes Care, vol. 33, no. 2, pp. 322–326, 2010.
[93] M. Monami, C. Lamanna, D. Balzi, N. Marchionni, and
E. Mannucci, “Sulphonylureas and cancer: a case-control
study,” Acta Diabetologica, vol. 46, no. 4, pp. 279–284, 2009.
[94] G. Libby, L. A. Donnelly, P. T. Donnan, D. R. Alessi, A. D.
M o r r i s ,a n dJ .M .M .E v a n s ,“ N e wu s e r so fm e t f o r m i na r ea t
lowriskofincidentcancer:acohortstudyamongpeoplewith
type 2 diabetes,” Diabetes Care, vol. 32, no. 9, pp. 1620–1625,
2009.
[95] D. Li, S. J. Yeung, M. M. Hassan, M. Konopleva, and J. L.
Abbruzzese, “Antidiabetic therapies aﬀect risk of pancreatic
cancer,” Gastroenterology, vol. 137, no. 2, pp. 482–488, 2009.
[96] A. DeCensi, M. Puntoni, P. Goodwin et al., “Metformin and
cancerriskindiabeticpatients:asystematicreviewandmeta-
analysis,”CancerPreventionResearch,vol.3,no.11,pp.1451–
1461, 2010.
[97] C. J. Currie, C. D. Poole, and E. A. M. Gale, “The inﬂuence of
glucose-lowering therapies on cancer risk in type 2 diabetes,”
Diabetologia, vol. 52, no. 9, pp. 1766–1777, 2009.
[98] X. Yang, R. C. W. Ma, W. Y. So et al., “Low triglyceride and
nonuse of statins is associated with cancer in type 2 diabetes
mellitus,” Cancer, vol. 117, no. 4, pp. 862–871, 2011.
[99] M. Bodmer, C. Becker, C. Meier, S. S. Jick, and C. R.
Meier, “Use of metformin and the risk of ovarian cancer:12 Journal of Oncology
a case-control analysis,” Gynecologic Oncology, vol. 132, no.
2, pp. 200–204, 2011.
[100] J. H. Lee, T. I. Kim, S. M. Jeon, S. P. Hong, J. H. Cheon,
a n dW .H .K i m ,“ T h ee ﬀects of metformin on the sur-
vival of colorectal cancer patients with diabetes mellitus,”
International Journal of Cancer. In press.
[101] S. Jiralerspong, S. L. Palla, S. H. Giordano et al., “Met-
formin and pathologic complete responses to neoadjuvant
chemotherapy in diabetic patients with breast cancer,” Jour-
nal of Clinical Oncology, vol. 27, no. 20, pp. 3297–3302, 2009.
[102] S. Bayraktar, L. F. Hernadez-Aya, X. Lei et al., “Eﬀe c to fm e t -
formin on survival outcomes in diabetic patients with triple
receptor-negative breast cancer,” Cancer, vol. 118, no. 5, pp.
1202–1211, 2012.
[103] S. Hadad, T. Iwamoto, L. Jordan et al., “Evidence for
biological eﬀects of metformin in operable breast cancer:
a pre-operative, window-of-opportunity, randomized trial,”
Breast Cancer Research and Treatment, vol. 128, no. 3, pp.
783–794, 2011.
[104] K. Hosono, H. Endo, H. Takahashi et al., “Metformin sup-
presses colorectal aberrant crypt foci in a short-term clinical
trial,” Cancer Prevention Research, vol. 3, no. 9, pp. 1077–
1083, 2010.
[105] M. E. Beckner, G. T. Gobbel, R. Abounader et al., “Glycolytic
glioma cells with active glycogen synthase are sensitive to
PTEN and inhibitors of PI3K and gluconeogenesis,” Labo-
ratory Investigation, vol. 85, no. 12, pp. 1457–1470, 2005.
[106] Y. P. Hwang and H. G. Jeong, “Metformin blocks migra-
tion and invasion of tumour cells by inhibition of
matrix metalloproteinase-9 activation through a calcium
and protein kinase Calpha-dependent pathway: phorbol-12-
myristate-13-acetate-induced/extracellular signal-regulated
kinase/activator protein-1,” British Journal of Pharmacology,
vol. 160, no. 5, pp. 1195–1211, 2010.
[107] K. N. Phoenix, F. Vumbaca, M. M. Fox, R. Evans, and K.
P. Claﬀey, “Dietary energy availability aﬀects primary and
metastaticbreastcancerandmetformineﬃcacy,”BreastCan-
cerResearchandTreatment,vol.123,no.2,pp.333–344,2010.
[108] A. Vazquez-Martin, C. Oliveras-Ferraros, S. Cuf´ ı et al., “The
anti-diabetic drug metformin suppresses the metastasis-
associated protein CD24 in MDA-MB-468 triple-negative
breast cancer cells,” Oncology Reports, vol. 25, no. 1, pp. 135–
140, 2011.
[109] B. K. Tan et al., “Metformin treatment exerts antiinvasive
and antimetastatic eﬀects in human endometrial carcinoma
cells,” JournalofClinicalEndocrinology&Metabolism,vol.96,
no. 3, pp. 808–816, 2011.
[110] B. G. Chittenden et al., “Polycystic ovary syndrome and the
r i s ko fg y n a e c o l o g i c a lc a n c e r :as y s t e m a t i cr e v i e w , ”Repro-
ductive BioMedicine Online, vol. 19, no. 3, pp. 398–405, 2009.
[111] Y. L. Pon, H. Y. Zhou, A. N. Y. Cheung, H. Y. S. Ngan, and
A. S. T. Wong, “p70 S6 kinase promotes epithelial to mesen-
chymal transition through snail induction in ovarian cancer
cells,” Cancer Research, vol. 68, no. 16, pp. 6524–6532, 2008.
[112] A. Vazquez-Martin, C. Oliveras-Ferraros, S. Del Barco, B.
Martin-Castillo, and J. A. Menendez, “The anti-diabetic
drug metformin suppresses self-renewal and proliferation
of trastuzumab-resistant tumor-initiating breast cancer stem
cells,” Breast Cancer Research and Treatment, vol. 126, no. 2,
pp. 355–364, 2011.
[113] A. Moustakas and C. H. Heldin, “Signaling networks guiding
epithelial-mesenchymal transitions during embryogenesis
and cancer progression,” Cancer Science, vol. 98, no. 10, pp.
1512–1520, 2007.
[114] A. Singh and J. Settleman, “EMT, cancer stem cells and drug
resistance: an emerging axis of evil in the war on cancer,”
Oncogene, vol. 29, no. 34, pp. 4741–4751, 2010.
[115] T. Blick, H. Hugo, E. Widodo et al., “Epithelial mesenchymal
transition traits in human breast cancer cell lines parallel
the CD44HI/CD24lO/-stem cell phenotype in human breast
cancer,” Journal of Mammary Gland Biology and Neoplasia,
vol. 15, no. 2, pp. 235–252, 2010.
[116] S. Cuf´ ı, A. Vazquez-Martin, C. Oliveras-Ferraros, B. Martin-
Castillo, J. Joven, and J. A. Menendez, “Metformin against
TGFβ-inducedepithelial-to-mesenchymaltransition(EMT):
from cancer stem cells to aging-associated ﬁbrosis,” Cell
Cycle, vol. 9, no. 22, pp. 4461–4468, 2010.
[117] J. Rehman, “Empowering self-renewal and diﬀerentiation:
the role of mitochondria in stem cells,” Journal of Molecular
Medicine, vol. 88, no. 10, pp. 981–986, 2010.
[118] A. Prigione et al., “Human induced pluripotent stem cells
harborhomoplasmicandheteroplasmicmitochondrialDNA
mutations while maintaining human embryonic stem cell-
like metabolic reprogramming,” Stem Cells, vol. 29, no. 9, pp.
1338–1348, 2011.
[119] U. E. Martinez-Outschoorn, M. Prisco, A. Ertel et al.,
“Ketones and lactate increase cancer cell ”stemness”, driving
recurrence, metastasis and poor clinical outcome in breast
cancer: achieving personalized medicine via metabolo-geno-
mics,” Cell Cycle, vol. 10, no. 8, pp. 1271–1286, 2011.